AMC
AMC Entertainment Holdings, Inc.
AMC has the edge over GENI overall, supported by stronger fundamentals and stronger modeled upside.
GENI
Genius Sports Limited
GENI has lower modeled downside risk, despite its lower overall score.
AMC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Stable | |
| Under pressure |
AMC's revenue is currently healthy, and its profitability and cash flow are stable, but its balance sheet is under pressure.
GENI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
GENI's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
AMC PE Valuation
AMC has no meaningful PE right now: it lost money over the past year.
GENI PE Valuation
GENI has no meaningful PE right now: it lost money over the past year.
AMC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
AMC has the edge over GENI on the outlook, with more favorable earnings and profitability expectations.
GENI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect GENI's losses to grow, with revenue growing. However, they disagree widely on these estimates.
AMC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.40 | +$0.94 |
| Q2 2026 | -$1.10 | -$0.28 |
| Q1 2026 | -$1.09 | -$0.18 |
| Q4 2025 | -$1.34 | -$0.28 |
| Q3 2025 | -$1.34 | +$0.29 |
| Q2 2025 | -$0.82 | +$0.67 |
| Q1 2025 | -$0.91 | +$0.38 |
| Q4 2024 | -$1.06 | +$1.31 |
AMC has the edge over GENI on earnings, with more consistent year-over-year improvement.
GENI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.68 | -$0.37 |
| Q1 2026 | -$0.61 | -$0.42 |
| Q4 2025 | -$0.43 | -$0.16 |
| Q3 2025 | -$0.47 | -$0.15 |
| Q2 2025 | -$0.31 | +$0.12 |
| Q1 2025 | -$0.19 | +$0.20 |
| Q4 2024 | -$0.27 | +$0.13 |
| Q3 2024 | -$0.32 | +$0.54 |
GENI is still losing money, but far less than before: $0.68 per share over the past year, against $3.94 at its worst in early 2022.
AMC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7B | +32% |
| Q2 2026 | $1.6B | +14% |
| Q1 2026 | $1B | +21% |
| Q4 2025 | $1.3B | -1.4% |
| Q3 2025 | $1.3B | -3.6% |
| Q2 2025 | $1.4B | +36% |
| Q1 2025 | $862.5M | -9.3% |
| Q4 2024 | $1.3B | +18% |
AMC's revenue is growing: $1.7B last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +12 points |
| Q2 2026 | 15% | +8.3 points |
| Q1 2026 | -4.4% | +13 points |
| Q4 2025 | 0% | -0.3 points |
| Q3 2025 | 2.8% | -2.6 points |
| Q2 2025 | 6.6% | +11 points |
| Q1 2025 | -17% | -5.5 points |
| Q4 2024 | 0.4% | +14 points |
AMC has the edge over GENI on profitability, with a higher operating margin.
GENI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $195.5M | +65% |
| Q1 2026 | $188M | +31% |
| Q4 2025 | $240.5M | +37% |
| Q3 2025 | $166.3M | +38% |
| Q2 2025 | $118.7M | +24% |
| Q1 2025 | $144M | +20% |
| Q4 2024 | $175.5M | +38% |
| Q3 2024 | $120.2M | +18% |
GENI has the edge over AMC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -14% | +54 points |
| Q1 2026 | -16% | -1.6 points |
| Q4 2025 | -8.4% | -4.3 points |
| Q3 2025 | -14% | -8.8 points |
| Q2 2025 | -68% | -46 points |
| Q1 2025 | -14% | +6.1 points |
| Q4 2024 | -4.1% | +23 points |
| Q3 2024 | -5% | +3.7 points |
GENI's operating margin was −14% last quarter, up 54 points from the same quarter a year ago.
AMC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $109.3M | +$190.4M |
| Q2 2026 | $190.1M | +114% |
| Q1 2026 | -$174.7M | +$242.3M |
| Q4 2025 | $43.3M | -62% |
| Q3 2025 | -$81.1M | +$11.1M |
| Q2 2025 | $88.9M | +$168.1M |
| Q1 2025 | -$417M | -$178.2M |
| Q4 2024 | $113.9M | +$263.8M |
AMC has the edge over GENI on cash generation, producing positive trailing cash flow while its opponent burns cash.
GENI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$87M | -$67.8M |
| Q1 2026 | -$68.2M | -$20M |
| Q4 2025 | $69.6M | -0.4% |
| Q3 2025 | $19.1M | +$41.8M |
| Q2 2025 | -$19.2M | -$16.5M |
| Q1 2025 | -$48.3M | -$21.3M |
| Q4 2024 | $69.9M | +559% |
| Q3 2024 | -$22.7M | -7493% |
GENI has burned cash in most quarters: −$66M over the past year, against −$20M the year before.
AMC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +24% | +175M shares |
| 1 year | +107% | +463M shares |
| 3 years | +767% | +793M shares |
| 5 years | +4063% | +875M shares |
AMC has 897M diluted shares, up 107% from a year ago.
GENI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.5% | +9.5M shares |
| 1 year | +10% | +25.7M shares |
| 3 years | +34% | +70.4M shares |
| 5 years | +85% | +128M shares |
| Available history | +56% | +100M shares |
GENI has the edge over AMC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
GENI hasn't bought back shares in the past year.
AMC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 9.2x | High |
| Q4 2025 | 12.2x | High |
| Q3 2025 | 12.2x | High |
| Q2 2025 | 10.7x | High |
| Q1 2025 | 18.6x | High |
| Q4 2024 | 14.3x | High |
AMC's net debt is about 4.0 years of its operating earnings (EBITDA), down from 12 years a year ago.
GENI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -12.5x | Net Cash |
| Q4 2024 | -6.3x | Net Cash |
| Q1 2024 | -7.5x | Net Cash |
| Q4 2023 | -15.2x | Net Cash |
| Q1 2021 | 4.3x | High |
| Q4 2020 | 5.5x | High |
| Q3 2020 | 9.1x | High |
GENI has more cash than debt.
AMC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.3 | Neutral |
| Stochastic | 65.4 | Neutral |
AMC's weekly RSI is 67 (neutral) and its Stochastic is 65 (neutral).
GENI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.6 | Neutral |
| Stochastic | 23.4 | Neutral |
GENI's weekly RSI is 46 (neutral) and its Stochastic is 23 (neutral).
AMC PE vs Communication Services Sector
AMC has no meaningful PE right now: it lost money over the past year.
GENI PE vs Communication Services Sector
GENI has no meaningful PE right now: it lost money over the past year.
AMC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.01 | 11% above |
| 20 week MA | $2.64 | 27% above |
| 50 week MA | $2.01 | 66% above |
| 100 week MA | $2.53 | 32% above |
| 200 week MA | $10.9 | 69% below |
AMC has the edge over GENI on trend strength, trading above more of its moving averages.
GENI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.28 | 2.9% below |
| 20 week MA | $6.73 | 9.4% below |
| 50 week MA | $6.77 | 9.9% below |
| 100 week MA | $8.60 | 29% below |
| 200 week MA | $7.35 | 17% below |
GENI is in a downtrend: it's below all five of its weekly moving averages, and 17% below its 200-week average.
AMC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.5 | $12.6 | -66% |
| 2021 | $12.6 | $142.6 | +1036% |
| 2022 | $142.6 | $44.0 | -69% |
| 2023 | $44.0 | $6.12 | -86% |
| 2024 | $6.12 | $4.00 | -35% |
| 2025 | $4.00 | $1.69 | -58% |
| 2026 YTD | $1.69 | $3.34 | +98% |
AMC has the edge over GENI on returns for 2026, with the stronger performance.
GENI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $16.6 | +68% |
| 2021 | $16.6 | $7.61 | -54% |
| 2022 | $7.61 | $3.27 | -57% |
| 2023 | $3.27 | $6.18 | +89% |
| 2024 | $6.18 | $8.75 | +42% |
| 2025 | $8.75 | $10.9 | +24% |
| 2026 YTD | $10.9 | $6.10 | -44% |
GENI is down 44% so far in 2026, after finishing higher in four of the previous six years.